MedPath

Gmax Biopharm LLC

Gmax Biopharm LLC logo
πŸ‡¨πŸ‡³China
Ownership
Holding, Subsidiary
Established
2010-09-02
Employees
153
Market Cap
-
Website
https://www.gmaxbiopharm.com

Clinical Trials

1

Active:0
Completed:0

Trial Phases

1 Phases

Phase 1:1

Drug Approvals

0

Drug Approvals

No drug approvals found

This company may not have drug approvals in our database

Clinical Trials

Distribution across different clinical trial phases (1 trials with phase data)β€’ Click on a phase to view related trials

Phase 1
1 (100.0%)

A Study of GMA301 in Subjects With Pulmonary Arterial Hypertension

Phase 1
Conditions
Pulmonary Arterial Hypertension
Interventions
Drug: Q4W GMA301 IV injections (1800 mg)
Drug: Q4W GMA301 IV injections (300 mg)
Drug: Q4W GMA301 IV injections (600 mg)
Drug: Q4W GMA301 IV injections (1000 mg)
Other: Q4W placebo IV injections
First Posted Date
2020-08-07
Last Posted Date
2022-01-14
Lead Sponsor
Gmax Biopharm LLC.
Target Recruit Count
48
Registration Number
NCT04503733
Locations
πŸ‡ΊπŸ‡Έ

Brigham and Women's Hospital, Boston, Massachusetts, United States

πŸ‡¨πŸ‡³

Peking Union Medical College Hospital - Dongcheng District, Beijing, China

πŸ‡¨πŸ‡³

Xiangya Hospital, Central South University, Changsha, China

and more 4 locations

News

No news found

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

Β© 2025 MedPath, Inc. All rights reserved.